IND213 These results from Bracelet (yet to be updated to May but almost certain to be strong) go a very long way toward validating IND213.
The results from IND213 were very impressive but always in doubt due to an unfortunate fluke. There was a built in bias in the data due to the test group having favourable CELTIL scores vs the control goup. I bielieve the Ecog scores were also skewed in favour of the test goup.
This was IMO the reason why ONC failed to secure partner or buyout and an immediate launch into P3.
But now we have Bracelet. Having two randomized trials showing statistical signifance in favour of Pelareorep is very impressive and gives a fresh look at IND213.
Now when ONC says, "a near doubling of OS" it is much more convincing that this is due to treatment affect rather than a lucky roll of the dice (during randomization).
I say again that for those close to this story this week may be the best buying opporutnity in the past 20 years.